This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|October 2, 2017
Sartorius Stedim Cellca Builds Laboratory and Office Facility in Germany
Author(s)BioPharm International Editors
Sartorius begins building a new, EUR 30-million (US$35.2 million) Cell Culture Technology Center in Ulm, Germany.
Advertisement
Sartorius Stedim Cellca is building a new EUR 30-million (US$35.2 million) Cell Culture Technology Center at Science Park III in Eselsberg, situated at the northwestern scientific hub in Ulm, Germany, the company announced on Sept. 28, 2017, at a groundbreaking ceremony that marked the official start of construction work.
So far, Sartorius Stedim Cellca has been working in a rented building in Laupheim, Germany. The new laboratory and office complex will approximately double the company’s space and is scheduled to be completed by the end of 2019. In addition, relocation to this zone will provide closer proximity to universities and research institutes that are based in Ulm’s Science Park.
Sartorius Stedim Cellca develops cell lines and protein production processes, licenses technologies for the production of proteins, and offers cell culture media. The company has been a part of the biopharma equipment supplier Sartorius Stedim Biotech since 2015 and currently employs around 90 people. Over the medium term, the company plans to extend its workforce to more than 120 people.
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
3
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5